menu
    • menu

    Looking for excipients offered by DKSH? Find information on DKSH's regulatory filings (DMFs), cGMP inspections, pricing availability, etc. on PharmaCompass.

    DKSH-PSE
    News
    DKSH India Earns Great Place To Work Certification for the 2nd Time

    09 Sep 2024

    // PRESS RELEASE

    DKSH Extends Cosucra Distribution Agreement In Australia And NZ

    14 Aug 2024

    // EXPRESSPHARMA

    DKSH and Kyowa Kirin Forge Strategic Partnership Across Asia-Pacific

    02 Aug 2024

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    DKSH

    Contact Supplier

    Website

    Chinacoat 2024

    Exhibiting

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/_XAjYFmynQw

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    DKSH is your trusted partner for companies looking to grow their business in Asia & beyond.

    Related CompaniesRelated Companies

    About

    DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It has been fostering growth for businesses in Asia and beyond for over 155 years. DKSH operates in 36 markets, is listed on the SIX Swiss Exchange, employs 33,100 specialists, and generated net sales of CHF 11.1 billion in 2021. It is the leading global distributor of innovative pharma ingredients for pharmaceutical synthesis and formulation. It offers a range of products, ranging from animal care products to packaging materials, intermediates to nutraceuticals, and APIs to excipients.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    DKSHSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Wiesenstrasse 8, P.O. Box 888 Zurich, Zurich 8034, CH
    Telephone
    Telephone
    +49 4037473411
    Client Email
    Email
    himali.pawaskar@dksh.com
    Client Website
    Website
    https://www.dkshdiscover.com/pim/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/dksh
    youtube
    YouTube
    http://www.youtube.com/@DkshGroup
    Twitter
    Twitter
    https://x.com/dkshgroup
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    CPHI Middle east

    CPHI Middle east

    Not Confirmed

    envelop Contact Supplier

    CPHI Middle east

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/dksh-party-content-34131.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/dksh-party-content-29458.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Performance Materials Brochure 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/dksh-party-content-13675.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    FDA approves record eight biosimilars in H1 2024; okays first interchangeable biosimilars for Eylea

    FDA approves record eight biosimilars in H1 2024; okays first interchangeable biosimilars for Eylea

    Biologics, or complex drugs that are derived from living organisms, have revolutionized treatment of various conditions such as cancer, autoimmune diseases, and chronic illnesses. In 2023, eight out of 10 of the world’s top-selling drugs were biologics, including Merck’s Keytruda, AbbVie’s Humira, and Sanofi’s Dupixent.Due to their high costs, accessibility of biologics has been a challenge. That’s why biosimilars, or game-changing copycats of biologics that provide highly similar yet more affordable alternatives to established biologics, are becoming popular.The first biosimilar — Sandoz’ Zarxio — was approved by the US Food and Drug Administration (FDA) in 2015. Its reference biologic was Amgen’s Neupogen (filgrastim).  Since then, the global market for biosimilars has been growing at an impressive pace — between 2015 and 2020, it grew at a whopping compounded annual growth rate (CAGR) of 78 percent, touching US$ 17.9 billion in size. It is expected to continue growing at a CAGR of 15 percent and reach a size of about US$ 75 billion by 2030.Major biosimilar players include Amgen, Sandoz, Samsung Bioepis, Pfizer, Biocon Biologics, Celltrion, Stada Arzneimittel, Accord Healthcare, Fresenius Kabi, Coherus Biosciences, Apotex, and Sanofi. The increasing demand for biosimilars has propelled growth in contract manufacturing. Some of the leading contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) that manufacture biosimilars are Polpharma Biologics, Catalent, Pfizer CentreOne, Lonza, Boehringer Ingelheim BioXcellence, Thermo Fisher Scientific, WuXi Biologics, and FUJIFILM Diosynth Biotechnologies.Access the Interactive Dashboard for Biosimilar Developments (Free Excel)Amgen, Sandoz top list of ‘approved biosimilars’; FDA okays 8 copycats in H1 2024Over the recent years, regulatory agencies like the FDA and the European Medicines Agency (EMA) have established rigorous approval pathways for biosimilars.Since 2015,  FDA has approved 53 biosimilars, while the EMA has approved 86 biosimilars. Among the US, European and Canadian markets, Amgen and Sandoz are tied in the first place with 13 approved biosimilars each. Samsung Biologics has nine approved biosimilars, followed by Pfizer with eight and Biocon Biologics with seven. In the first half of this year, FDA set a record by approving eight biosimilars — the highest for H1 of any year. EMA has okayed six biosimilars so far in 2024.In 2023, five biosimilars were approved by the FDA with just one being okayed in the first half. The year marked the end of exclusivity for Humira after 20 years, in which it netted a total of US$ 200 billion in sales. AbbVie’s flagship autoimmune drug has a record 10 biosimilars.Johnson & Johnson’s Stelara also lost exclusivity in 2023 and as many as 11 drugmakers hope to bring its biosimilars to the market. Amgen’s Wezlana was the first biosimilar to Stelara, and it was approved as interchangeable by FDA in October last year.Access the Interactive Dashboard for Biosimilar Developments (Free Excel) FDA approves first interchangeable biosimilar for Eylea, cuts regulatory feeDeveloping a biosimilar costs both money and time. According to Pfizer, developing a biosimilar can take five to nine years and cost over US$ 100 million, not including regulatory fees.In October 2023, FDA slashed its fees with the program fee at US$ 177,397, down from US$ 304,162. The application fees for products that require clinical data has been set at US$ 1,018,753, down from US$ 1,746,745. The application fee for products that don’t require clinical data has been set lower — at US$ 509,377 —  down from US$ 873,373 set earlier. This reduction in application fee has propelled demand for contract manufacturing of biosimilars.There has also been a rise in approvals of interchangeable biosimilars this year. Interchangeable biosimilars meet additional requirements and may be substituted for its reference product by a pharmacist without consulting the prescriber. This year saw FDA approve the first interchangeable biosimilars for bone cancer drug denosumab (Prolia and Xgeva) in Jubbonti and Wyost as well as for eculizumab (Soliris) in Bkemv.In May, FDA approved the first interchangeable biosimilars for eye drug aflibercept (Eylea) in Opuviz and Yesafili. Other biosimilars approved in 2024 include Simlandi for adalimumab (Humira), Tyenne for tocilizumab (Actemra), Selarsdi for ustekinumab (Stelara), and Hercessi for trastuzumab (Herceptin).Access the Interactive Dashboard for Biosimilar Developments (Free Excel) Merck’s Keytruda, BMS’ Opdivo, Novartis’ Cosentyx brace for biosimilar competitionHealthcare spending in the US is projected to rise from US$ 4.5 trillion in 2022 to US$ 6 trillion by 2027. While biologics involve just two percent of prescriptions, they account for 46 percent of all pharmaceutical spending. In 2022, US$ 252 billion was spent on biologics.Biosimilar-related savings in 2023 were estimated to be US$ 9.4 billion in the US and € 10 billion (US$ 10.68 billion) in Europe. With expensive and widely used drugs like AbbVie’s Humira, J&J’s Stelara, and Regeneron’s Eylea coming under competition, US savings are projected to reach US$ 181 billion through 2027. Between 2026 and 2032, about 39 blockbusters are set to lose exclusivity in the US and Europe. Merck’s Keytruda (pembrolizumab) was the world’s top-selling drug last year, generating US$ 25 billion in sales. Its patent is set to expire in 2028 with sales expected to drop 19 percent to US$ 27.4 billion in 2029 from US$ 33.7 billion the previous year. Samsung Bioepis and Amgen initiated phase 3 trials of pembrolizumab in April and May of this year, respectively.Opdivo (nivolumab), belonging to the same class of drugs, competes with Keytruda and is also set to lose patent protection in 2028. It hauled in US$ 10 billion in total global sales in 2023 for Bristol Myers Squibb. The key patents of Novartis’ Cosentyx (secukinumab) are set to expire between 2025 and 2026. Cosentyx saw sales of US$ 5 billion in 2023. Taizhou Mabtech Pharmaceutical and Bio-Thera Solutions are conducting phase 3 trials of secukinumab.Access the Interactive Dashboard for Biosimilar Developments (Free Excel) Our viewWith over 2 billion people worldwide unable to access life-saving medicines, biosimilars hold the key to healthcare accessibility. In 2023, a record 13 biosimilars were launched in the market — the highest for a single year. And this included nine much-anticipated biosimilars to AbbVie’s Humira.  In April this year, FDA announced a Biosimilars Action Plan to streamline the development of biosimilars. With a sharp focus on biosimilars, we expect more records to be broken in the near term. New launches of biosimilars to drugs like J&J’s Stelara, Regeneron’s Eylea and Merck’s Keytruda will surely help in creating new records.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2339

    https://www.pharmacompass.com/radio-compass-blog/fda-approves-record-eight-biosimilars-in-h1-2024-okays-first-interchangeable-biosimilars-for-eylea

    #PharmaFlow by PHARMACOMPASS
    27 Jun 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    DKSH India Earns Great Place To Work Certification for the 2nd Time
    DKSH India Earns Great Place To Work Certification for the 2nd Time

    09 Sep 2024

    // PRESS RELEASE

    https://www.dksh.com/in-en/home/media/news?id=en-78576f61-bd53-4629-8de3-efd14ab80b96:1

    PRESS RELEASE
    09 Sep 2024
    Share Share
    DKSH Extends Cosucra Distribution Agreement In Australia And NZ
    DKSH Extends Cosucra Distribution Agreement In Australia And NZ

    14 Aug 2024

    // EXPRESSPHARMA

    https://www.expresspharma.in/dksh-extends-exclusive-distribution-agreement-with-cosucra-in-australia-and-new-zealand/

    EXPRESSPHARMA
    14 Aug 2024
    Share Share
    DKSH and Kyowa Kirin Forge Strategic Partnership Across Asia-Pacific
    DKSH and Kyowa Kirin Forge Strategic Partnership Across Asia-Pacific

    02 Aug 2024

    // PRESS RELEASE

    https://www.dksh.com/global-en/home/media/news?id=en-9f2da14e-9932-4986-805f-2c95a11f1734:1

    PRESS RELEASE
    02 Aug 2024
    Share Share
    DKSH Philippines Wins “WACKER Platinum Distributor of the Year Award 2024
    DKSH Philippines Wins “WACKER Platinum Distributor of the Year Award 2024

    01 Aug 2024

    // PRESS RELEASE

    https://www.dksh.com/global-en/home/media/news?id=en-1777c1e2-cf2c-4256-a72c-9dbd4f36ba23:1

    PRESS RELEASE
    01 Aug 2024
    Share Share
    DKSH and Ortoalresa Enter Strategic Partnership in Vietnam
    DKSH and Ortoalresa Enter Strategic Partnership in Vietnam

    26 Jul 2024

    // PRESS RELEASE

    https://www.dksh.com/global-en/home/media/news?id=en-020e96f9-7af8-4a81-a91c-b81eb449b83b:1

    PRESS RELEASE
    26 Jul 2024
    Share Share
    DKSH Receives Regional Headquarters Certificate in Shanghai
    DKSH Receives Regional Headquarters Certificate in Shanghai

    26 Jul 2024

    // PRESS RELEASE

    https://www.dksh.com/global-en/home/media/news?id=en-07810d8e-3869-4b37-b4f0-b49f4302f547:1

    PRESS RELEASE
    26 Jul 2024
    Share Share

    LISTED APIs

    read-more
    read-more
    Contact Supplier
    • FDA
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDKSH is your trusted partner for companies looking to grow their business in Asia & beyond.

    Ajmaline

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It has been fostering growth for businesses in Asia and beyond for over 155 years. DKSH operates in 36 markets, is listed on the SIX Swiss Exchange, employs 33,100 specialists, and generated ne...
    DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It has been fostering growth for businesses in Asia and beyond for over 155 years. DKSH operates in 36 markets, is listed on the SIX Swiss Exchange, employs 33,100 specialists, and generated net sales of CHF 11.1 billion in 2021. It is the leading global distributor of innovative pharma ingredients for pharmaceutical synthesis and formulation. It offers a range of products, ranging from animal care products to packaging materials, intermediates to nutraceuticals, and APIs to excipients.
    DKSH Company Banner

    01

    Ajmaline

    Switzerland
    arrow
    Chinacoat 2024
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDKSH is your trusted partner for companies looking to grow their business in Asia & beyond.

    DKSH

    DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It has been fostering growth for businesses in Asia and beyond for over 155 years. DKSH operates in 36 markets, is listed on the SIX Swiss Exchange, employs 33,100 specialists, and generated net sales of CHF 11.1 billion in 2021. It is the leading global distributor of innovative pharma ingredients for pharmaceutical synthesis and formulation. It offers a range of products, ranging from animal care products to packaging materials, intermediates to nutraceuticals, and APIs to excipients.

    About the Company : DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It has been fostering growth for busi...

    DKSH Company Banner

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • FDA
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDKSH is your trusted partner for companies looking to grow their business in Asia & beyond.

    Aluminium Hydroxide

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It has been fostering growth for businesses in Asia and beyond for over 155 years. DKSH operates in 36 markets, is listed on the SIX Swiss Exchange, employs 33,100 specialists, and generated ne...
    DKSH, founded with the goal of improving peop